Nefazodone lithium

Rickels K, Schweizer E, Clary C, et al Nefazodone and imipramine in major depression a placebo-controlled trial. Br J Psychiatry 164 802-805, 1994 Riddell EG Studies on Li" transport using 7Li and 61i nuclear magnetic resonance, in Lithium and the Cell. Edited by Birch NJ. San Diego, CA, Academic Press, 1991, pp 85-98... 

Sharp T, Bramwell SR, Lambert P, et al Effect of short- and long-term administration of lithium on the release of endogenous 5-HT in the hippocampus of the rat in vivo and in vitro. Neuropharmacology 30 977-984, 1991 Sharpley AL, Cowen PJ Effect of the pharmacological treatment on sleep of depressed patients. Biol Psychiatry 37 85-98, 1995 Sharpley AL, Walsh AES, Cowen PJ Nefazodone—a novel antidepressant— may increase REM sleep. Biol Psychiatry 31 1070-1073, 1992 Shaw DM, Harris B, Lloyd AT, et al A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 149 515-517, 1986 Shaw PJ, Ince PG A quantitative autoradiographic study of H-3-Kainate binding sites in the normal human spinal-cord, brain stem, motor cortex. Brain Res 641 39-45, 1994... 

In 12 healthy volunteers, there were no clinically significant alterations in blood concentrations of lithium or nefazodone and its metabolites when the drugs were co-... 

Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, Ingrand I, Decourt JP. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. Eur J Clin Pharmacol 1999 54(12) 923-8. 

Hawley C, Sivakumaran T, Huber TJ, Ige AK. Combination therapy with nefazodone and lithium safety and tolerability in fourteen patients. Int J Psychiatry Clin Pract 1998 2 251-4. 

In 12 healthy volunteers, there were no clinically significant alterations in blood concentrations of lithium or nefazodone and its metabolites when the drugs were coadministered (587). The addition of lithium for 6 weeks to nefazodone in 14 treatment-resistant patients produced no serious adverse effects and no dropouts (588). Lithium augmentation of nefazodone in 13 treatment-resistant depressed patients was associated with a variety of annoying adverse effects, but none led to treatment withdrawal (589). 

Hawley C, Sivakumaran T, Ochocki M, Ratnam S, Huber T. A preliminary safety study of combined therapy with nefazodone and lithium. Int J Neuropsychopharmacol 1999 2(Suppl 1) S30-1. 

Activation and agitation may represent the induction of a bipolar state, especially a mixed dysphoric bipolar II condition sometimes associated with suicidal ideation, and require the addition of lithium, a mood stabilizer or an atypical antipsychotic, and/or discontinuation of nefazodone... 

Clinically important, potentially hazardous interactions with desvenlafaxine, dextromethorphan, dihydroergotamine, ephedra, ergot, fluoxetine, fluvoxamine, isocarboxazid, linezolid, lithium, MAO inhibitors, meperidine, methysergide, naratriptan, nefazodone, paroxetine, phenelzine, rizatriptan, sertraline, sumatriptan, tranylcypromine, tryptophan, venlafaxine, verapamil, zolmitriptan, zuclopenthixol... 

For treatment-resistant patients who do not respond to SSRIs or TCAs, or to the combination of TCAs/SSRIs with benzodiazepines, other antidepressants have shown at least some beneficial effects in alleviating PD symptoms (e.g. mirtazapine, moclobemide, nefazodone, phenelzine, reboxetine, and venlafaxine). Other agents have also been reported to exert beneficial effects in PD, especially when combined with SSRIs/TCAs (lithium, pindolol, and propranolol). In cases where all treatments have failed, valproate or olanzapine should be considered.2 - ° In order to optimize treatment, patients should avoid or reduce the consumption of compounds that could potentially induce/exacerbate panic attacks (e.g. caffeine, alcohol, and nicotine) and should exercise regularly. i... 

In a study in 12 healthy subjects, nefazodone 200 mg twice daily was given alone for 5 days. After a washout period, lithium was given for 11 days, in escalating doses from 250 mg twice daily to 500 mg twice daily. When therapeutic steady-state lithium levels were achieved nefazodone 200 mg twice daily was added for 5 days. The pharmacokinetics of both nefazodone and lithium were unaltered by concurrent use, although there were some small changes in the pharmacokinetics of the nefazodone metabolites. However, since the combination was well tolerated, no dosage adjustments were considered necessary on concurrent use. ... 

---